Nachrichten zur ImmunoGen Inc. Aktie

1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever

This will go down in history as an incredible year for stocks. The S&P 500 hit a new all-time high…

FDA grants full approval to AbbVie/ImmunoGen drug Elahere

…

AbbVie Sees More Than $80 Billion Demand for Bond Sale

AbbVie is selling around $15 billion of bonds in the US investment-grade market to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics…

AbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel

Pharmaceutical giant AbbVie Inc. is selling around $15 billion of bonds in the US investment-grade market on Thursday to help…

AbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&A

Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions…

AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen

AbbVie Inc.’s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of…

ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?

ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…

ImmunoGen spikes as HSR waiting period for AbbVie deal expires

…

Targinta’s CEO to BioStock: “Strong interest in ADCs in 2023”

During 2023, we have witnessed several significant business deals involving Antibody-drug conjugates (ADC), both in preclinical and clinical phase. This…

How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry

ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry…

ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA

The FDA grants priority review to ImmunoGens (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for…

Immunogens AbbVie Deal: Key Insights For Investors And Traders

…

ImmunoGen downgraded on Wall Street expecting AbbVie deal success

…

Abbvies $10bn swoop puts the spotlight on antibody-drug conjugates stocks

AbbVie Inc has announced the acquisition of ImmunoGen (NASDAQ:IMGN) for $10.1 billion in cash - a deal that takes into the…

AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors…

Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More

AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by…

AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology

…

AbbVies $10bn Deal For ImmunoGen: Fundamentals And Rationale Explained

…

Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion

Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the…

AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio

…

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

IMGN stock soared after AbbVie agreed to buy ImmunoGen for $10.1 billion, offering a rich premium for the maker of…

Immunogen shares surge on news of takeover by AbbVie By Investing.com

Immunogen shares surge on news of takeover by AbbVie…

Pharmaceutical company AbbVie buying ImmunoGen in $10.1 billion deal

…

AbbVie to acquire cancer drugmaker ImmunoGen for $10B cash (update)

…

AbbVie signs $10 billion deal to buy cancer drugmaker ImmunoGen

…

AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio By Reuters

AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio…

: AbbVie $10.1 billion deal to buy ImmunoGen values the stock at a 95% premium

AbbVie Inc. ABBV announced Thursday an agreement to buy cancer treatment developer ImmunoGen Inc. IMGN in a cash deal valued…

ImmunoGen: Elahere Data Mid-2024 To Expand Targeted Population

…

Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock?

Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.…

Goldman starts ImmunoGen at neutral, cites valuation

…

4 Stocks to Invest in for Remarkable Earnings Acceleration

Invest in stocks such as Confluent (CFLT), Pinterest (PINS), ICON (ICLR) and ImmunoGen (IMGN) for solid earnings acceleration.…

ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

ImmunoGens (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The company…

Zscaler Stock, DoorDash, Immunogen, Ferrari, 25 Other Stocks Enter IBD Watchlists

Zscaler stock, AppFolio, Brown & Brown, Consol Energy and Copart are among the 29 new stocks on IBDs proprietary stock…

ImmunoGen, Inc. (IMGN) Q3 2023 Earnings Call Transcript

…

ImmunoGen (IMGN) Q3 Earnings and Revenues Top Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 400% and 6.02%, respectively, for the quarter ended September 2023. Do the…

Analyzing The Acquisition Potential Of ImmunoGen

…

3 Solid Stocks to Buy for Superb Earnings Acceleration

Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.…

ImmunoGen draws Perform rating at Oppenheimer on recent rally

…

ImmunoGen appoints Lauren White as CFO

…

ImmunoGen gains as J.P. Morgan upgrades to overweight on favorable outlook for Elahere

…

ImmunoGen To Collaborate With Takeda To Develop, Commercialize Elahere In Japan

TOKYO (dpa-AFX) - ImmunoGen, Inc. (IMGN), a biopharmaceutical company, announced on Monday that it has entered into an exclusive collaboration…

ImmunoGen inks deal with Takeda for cancer drug Elahere

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ImmunoGen stock jumps after licensing deal with Japan’s Takeda Pharmaceutical

Shares of ImmunoGen Inc. IMGN jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with…

Insiderhandel: SVP & CHIEF BUSINESS OFFICER verkauft Aktien von ImmunoGen im Wert von 1.422.982$

Coen, Stacy Ann - Vorstand - Tag der Transaktion: 2023-08-09...…

Insiderhandel: PRIN. FIN & ACCTG. OFF. verkauft Aktien von ImmunoGen im Wert von 2.602.261$

Lentini, Renee - Vorstand - Tag der Transaktion: 2023-08-02...…

ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat

ImmunoGens (IMGN) Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. The company, however, did not issue any…

Form 10-Q ImmunoGen, Inc. For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

ImmunoGen Shares Fall After Medical Chiefs Exit, Spending Outlook

ImmunoGen Shares Fall After Medical Chief's Exit, Spending Outlook...…

ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 87.50% and 94.09%, respectively, for the quarter ended June 2023. Do the…

AKTIONÄR-Tipp Immunogen springt kräftig an: Hammer-Zahlen beflügeln

Die Biotech-Schmiede Immunogen hat in diesem Jahr mit sehr starken Daten zu Elahere für Aufsehen gesorgt. DER AKTIONÄR nahm diese…